Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 195 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint... February 21, 2024 Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma June 11, 2024 Teen Created App To Help His Non-Verbal Sister And Others Like... October 28, 2021 Load more HOT NEWS FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe... Nivolumab Injections Could Make Treatment Easier for More People with Cancer Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... How to Get More Support From Your Oncology Pharmacist During Cancer
